glp-1 weight loss oral Lilly orforglipron phase 3 trial Article » PBD

Currently, there is no established causal link between tirzepatide use and increased risk of blood clots (venous thromboembolism or arterial thrombosis) based on available clinical trial data and post-marketing surveillance

Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide

Substantial societal return : Expanding access to anti-obesity medications yields returns exceeding 13% annuallycomparable to early childhood education investments and nearly double U.S

Additionally, there were more deaths in the Tirzepatide group than semaglutide (12 vs 1)

[DOI] [PubMed] [Google Scholar] 30.Tonneijck L, et al

Normal bowel movements can vary among individuals for several reasons, including dietary habits, supplement intake, and activity levels